Pharmenterprises Biotech

Pharmenterprises is a Russian biotechnology company dedicated to the discovery and development of innovative small molecule therapeutics and vaccines, primarily targeting respiratory and infectious diseases. Headquartered in the Skolkovo Innovation Center, the company leverages its expertise in glutarimide derivatives to create novel treatments for conditions with high unmet medical needs. Its lead clinical candidate, XC8, is an oral anti-chemokine agent being evaluated in Phase 2 trials for the treatment of asthma. Additionally, Pharmenterprises is advancing Treamid for post-COVID-19 lung fibrosis rehabilitation and XC221 for viral respiratory infections. The company's pipeline also includes UniFluVec, a recombinant influenza vaccine in early-stage clinical development.